tDCS for Fatigue in Sjogren's Syndrome

Sjogren's Syndrome Clinical Trial

Official title:

Effects of Transcranial Direct Current Stimulation (tDCS) on Fatigue in Patients With Primary Sjogren's Syndrome: a Double-blinded Randomized Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04119128
• Other study ID #: FederalUnivOfSaoPaulo
• Status: Completed
• Phase: N/A
• Start date: June 3, 2019
• Est. completion date: April 1, 2020

Study information

• Verified date: May 2020
• Source: Federal University of São Paulo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Sjogren's Syndrome (SS) is an autoimune disease of unknown etiology characterized by lymphocytic infiltration of the exocrine glands and other organs. patients usually presents with xerophthalmia, xerostomia, fatigue and other symptoms. Fatigue has often been reported as the biggest problem and the most difficult symptom patients have to deal with. Fatigue management in pSS is difficult. However, in other diseases such as Parkinson disease, post-polio syndrome and multiple sclerosis the use of Transcranial Direct Current Stimulation (tDCS) has recently been studied and has shown effectiveness. The overarching objective of this study is to examine the effect of a tDCS protocol in patients with pSS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: April 1, 2020
• Est. primary completion date: April 1, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Women

• Age between 18 and 65 years old;

• Diagnosis of primary Sjogren's Syndrome according to American-European Criteria;

• Stable pharmacological therapy for at least 3 months;

• Complaints of fatigue as assessed by Fatigue Severity Scale (FSS>5).

• Complaints of fatigue for more than 3 months.

Exclusion Criteria:

• Heart, coronary, respiratory, renal, or hepatic uncompensated insufficiencies;

• Uncompensated systemic arterial hypertension;

• Unable to answer the questionnaires.

• Severe depression (with a score > 30 in the Beck Depression Inventory)

• History of epilepsy or syncope

• Implanted brain metallic devices

• Established cognitive impairment

• Traumatic brain injury with residual neurological deficits

Related Conditions & MeSH terms

• Fatigue
• Sjogren's Syndrome
• Syndrome

Intervention

Device:
• Active Transcranial Direct Current Stimulation
Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.
• Sham Transcranial Direct Current Stimulation
Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.

Locations

Country	Name	City	State
Brazil	FUSaoPaulo	Sao Paulo	SP

Sponsors (3)

Lead Sponsor	Collaborator
Federal University of São Paulo	Universidade Federal do Amapá, University of Pittsburgh

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in Hypothalamic-pituitary-adrenal (HPA) axis activity	Salivary cortisol	Will be measured immediately before and immediately after the first day of stimulation and immediately before and immediately after the last day (5th) day of stimulation.
Other	Change in Sleep Quality	Will be assessed with Pittsburgh Sleep Quality Index (PSQI). PSQI is a self-report questionnaire that assesses sleep quality. It's composed by nineteen individual items that generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. The global PSQI score ranges from 0 to 21, where lower scores denote a healthier sleep quality.	Will be measured at baseline, on the 5th day of stimulation (immediately after the end of stimulation), 15 days after the end of stimulation and 30 days after the end of stimulation
Other	Change in Depression	Will be assessed using Beck Depression Inventory (BDI). BDI is a 21-item self-report inventory, for measuring the severity of depression. The items are scored from 0 to 3 points. Higher values indicate higher severity of depression.	Will be measured at baseline, on the 5th day of stimulation (immediately after the end of stimulation), 15 days after the end of stimulation and 30 days after the end of stimulation
Other	Change in Patient Self Assessment	Subjects will rate their assessment using verbal response and a visual analog scale (0-10). They will rate: Anxiety, stress and sleepiness.	Will be measured at baseline, on the 5th day of stimulation (immediately after the end of stimulation), 15 days after the end of stimulation and 30 days after the end of stimulation
Primary	Change in Fatigue	Will be assessed with Fatigue Severity Scale (FSS). FSS is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders. The items are scored on a 7-point scale. Higher values indicate higher severity of fatigue.	Change in fatigue from baseline to 15 days after the end of stimulation.
Secondary	Change in Profile of Fatigue	Will be assessed with Profile of Fatigue and Discomfort - Sicca Symptoms Inventory (short form) (Profad-SSI-SF). Profad-SSI-SF is a 19-item questionnaire assessing the subjective aspects of the symptoms of Sjogren's Syndrome, including fatigue, based on the patient's perception. The items are scored from 0 to 7 points. Higher values indicate higher severity of fatigue.	Will be measured at baseline, on the 5th day of stimulation (immediately after the end of stimulation), 15 days after the end of stimulation and 30 days after the end of stimulation
Secondary	Change in Symptoms severity	Will be assessed with EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI). ESSPRI is a very simple index designed to measure patients' symptoms of patients with Sjogren's Syndrome. ESSPRI is completed by the patient and it contains just three items to be given a score between 0-10: for pain, fatigue and dryness, the final ESSPRI score is the mean of all three scores and therefore also between 0-10. Higher values indicate higher severity of symptoms.	Will be measured at baseline, on the 5th day of stimulation (immediately after the end of stimulation), 15 days after the end of stimulation and 30 days after the end of stimulation
Secondary	Change in Quality of Life	Will be assessed with 12-Item Short-Form (SF-12). The SF-12 is a multipurpose short form survey with 12 questions. The SF-12 is weighted and summed to provide easily interpretable scales for physical and mental health. Physical and Mental Health Composite Scores (PCS & MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.	Will be measured at baseline, on the 5th day of stimulation (immediately after the end of stimulation), 15 days after the end of stimulation and 30 days after the end of stimulation
Secondary	Change in Patient Global Assessment	Subjects will rate their global assessment using verbal response and a visual analog scale (0-10). They will rate: Global health.	Will be measured after the 1st, 5th day of stimulation, 15 days after the end of stimulation and 30 days after the end of stimulation.
Secondary	Change in Adverse Events	Subjects will complete a structured questionnaire to assess potential adverse events of stimulation	Will be measured up to 30 days after the end of stimulation.